Targeting regulatory T cells in tumor immunotherapy

Affiliations

¹ 1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] School of Medicine, University of Queensland, St Lucia, Queensland, Australia.
² Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
³ 1] School of Medicine, University of Queensland, St Lucia, Queensland, Australia [2] Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

Comment

Mark J Smyth et al. Immunol Cell Biol. 2014 Jul.

. 2014 Jul;92(6):473-4.

doi: 10.1038/icb.2014.33. Epub 2014 Apr 29.

¹ 1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] School of Medicine, University of Queensland, St Lucia, Queensland, Australia.
² Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
³ 1] School of Medicine, University of Queensland, St Lucia, Queensland, Australia [2] Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

No abstract available

Comment on

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. Bulliard Y, et al. Immunol Cell Biol. 2014 Jul;92(6):475-80. doi: 10.1038/icb.2014.26. Epub 2014 Apr 15. Immunol Cell Biol. 2014. PMID: 24732076